Creating a single new prescription drug is currently estimated to cost $2.6 billion dollars. This is a sum so vast that only a small number of companies can afford to even consider the possibility. It is also a figure which is overshadowed by one major factor: failure. A staggeringly small number of medications are ever successful. As few as … [Read more...] about Pharmaceutical research: the price of failure
The 2016 Human development index (HDI) report has been published. It is a list of 188 countries in ranked order, listed according to a set of criteria used to determine the quality of life in each country. It comes out at a time of large scale political instability with nationalistic speeches focusing on making countries great again heard … [Read more...] about The Human Development Index, what makes a country great?
Some cancer medications cost too much for too little benefit, suggests a study published last year in the British Medical Journal. The study indicates that many chemotherapeutic drugs are only shown to increase life expectancy in those with stage IV (metastatic) cancer by a few months. Yet these treatments can incur costs as high as six … [Read more...] about A few more months for a six figure sum, the ethics of cancer medications
U.S. President Donald Trump’s announcement of his intention to reduce funds to numerous government departments has many worried. One primary target of the cuts is the National Institutes of Health (NIH). Attempts were also made to repeal the Affordable Care Act (ACA) (often referred to as Obamacare) though a revolt amongst the republican party saw … [Read more...] about Trump to remove critical funds from the CDC?
Modern science is in an arms race with mosquito borne disease and climate change is bringing the mosquito threat to the doorsteps of yet more nations. Recent headlines are placing emphasis on the views of the new President of the United States Donald Trump and many of his cabinet appointees, rejecting the scientific consensus on climate change. … [Read more...] about Mosquito-borne illness in 2017
A drug trial for a Merck & Co Inc. (MSD) medication verubecestat has been stopped because it was very unlikely to show a significant difference in Alzheimers disease progression compared to a placebo control. This was a phase III clinical trial in patients with early dementia. The setback comes after months of positive media attributed … [Read more...] about Failed trials for Alzheimer’s may mean a key theory is wrong
Worrying reports have surfaced regarding Trump’s new healthcare secretary and his views on anti-vaccination. Tom Price now heading a department backed by a budget of over $1 trillion USD, is a member of a group that describes mandatory vaccination as “equivalent to human experimentation”. The group itself, the Association of American Physicians and … [Read more...] about Donald Trump’s stance on anti-vaccination
Hyderus undertakes healthcare research in Argentina Hyderus was recently commissioned to undertake research into the market for innovative oncology products in Argentina, which is an emerging country in terms of its healthcare status on the world stage. An in-depth research project was undertaken, which looked at the Argentine health system, … [Read more...] about Patagonia/Argentina – what’s our connection?
Hyderus - It’s all about Community Since Hyderus first arrived in the small Welsh village of Cwmfelinfach some sixteen years ago, it has been very keen to invest and support the local community and wider area. Investment in local businesses has been one of the company’s priorities and playing an important role in community life is integral to … [Read more...] about Hyderus – it’s all about Community!
A separate article which is included in PME and written exclusively by Mark Chataway, summarises the “Five Myths about emerging markets”. Mark challenges the current thinking with his fact-defying answers to the following statements : You can have an ‘emerging markets strategy’ Mark stresses that emerging markets are intrinsically … [Read more...] about Mark’s five myths about emerging markets made simple!